The presence or absence of nonictal allodynia can be used to identify migraine sufferers who will likely respond to galcanezumab, according to a study published online Feb. 14 in Cephalalgia. Sait Ashina, M.D., from the Beth Israel Deaconess Medical Center in Boston, and colleagues assessed whether it is possible to…